I ran a story about Bafetinib on MyelomaNews.com yesterday:
CYTRX : CytRx’s Bafetinib Demonstrates Ability to Prevent Cancer-Related Bone Loss
Interesting that the company chose to quote Dr. Berenson in their press release. You remember Dr. Berenson, right? Recall yesterday’s article,
Have Multiple Myeloma Researchers Stopped Searching For A Cure? Not The Institute For Myeloma & Bone Cancer Research.
Dr. Berenson is actively involved in researching how multiple myeloma affects bone health. For example, he is a big proponent of Zometa, an IV bisphosphonate. It is all just a coincidence, but Dr. Berenson sure does get around!
Here is another look at bafetinib by Pharmaceuticals-Business-Review.com:
Bafetinib prevents cancer-related bone loss: CytRx
CytRx has announced results from a series of preclinical studies that demonstrated that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.
The studies evaluated the effect of bafetinib on bone cells (osteoclasts) from multiple myeloma patients.
The study results showed that in two model systems, bafetinib significantly suppressed the activity of osteoclasts and inhibited bone resorption in a dose-dependent manner.
CytRx president and CEO Steven Kriegsman said results from these studies showed that this kinase inhibitor could present a new therapeutic option to reduce skeletal complications in cancer patients.
“Reduction of bone loss represents one of multiple oncology indications in which bafetinib could represent an effective treatment,” Kriegsman said.
CytRx is currently assessing bafetinib in three ongoing clinical trials: a Phase 2 proof-of-concept prostate cancer clinical trial in patients with advanced cancers; a Phase 2 proof-of-concept clinical trial in patients with high-risk B-cell chronic lymphocytic leukemia; a pharmacokinetic clinical trial in patients with recurrent brain tumours
This reads like bafetinib can be used similarly to Zometa and Aredia, to help strengthen our bones and possibly slow the myeloma down. It isn’t clear to me why this is any better than either of these other two bisphosphonates.
And what about Prolia and Amgen’s denosumab (Xgeva)? Is there really room in the marketplace for all of these drugs? Will this affect FDA approvals?
If you recall, the FDA rarely approved new drugs which are similar to others unless they:
a) Show significant improvement in time to disease progression or extended life expectancy
b) Can demonstrate similar results, while significantly reducing dangerous side-effects
I don’t know enough about all of this to do a compare/contrast article yet. Let’s see what I can come up with.
In the meantime, it seems clear the mad rush is on to produce drugs which may be helpful to multiple myeloma patients. Great! But now, about that cure…
Feel good and keep smiling! Pat